Literature DB >> 26691631

Performance of magnetic resonance elastography in primary sclerosing cholangitis.

John E Eaton1, Bogdan Dzyubak2, Sudhakar K Venkatesh2, Thomas C Smyrk3, Gregory J Gores1, Richard L Ehman2, Nicholas F LaRusso1, Andrea A Gossard1, Konstantinos N Lazaridis1.   

Abstract

BACKGROUND AND AIM: Liver stiffness (LS) measured by magnetic resonance elastography (MRE) is emerging as an important biomarker in chronic liver diseases. We examined the diagnostic performance of MRE, factors associated with an increased LS and the prognostic value of LS as measured by MRE among patients with primary sclerosing cholangitis (PSC).
METHODS: We performed a retrospective review of 266 patients with PSC to examine whether LS was associated with the primary endpoint of hepatic decompensation (ascites, variceal hemorrhage and hepatic encephalopathy). The ability of MRE to differentiate stages of fibrosis was examined in a subset of patients who underwent a liver biopsy (n = 20).
RESULTS: An LS of 4.93 kPa was the optimal point to detected F4 fibrosis (sensitivity, 1.00; 95% confidence interval (CI), 0.40-1.00; specificity, 0.94; 95%CI, 0.68-1.00). While a serum alkaline phosphatase <1.5 times the upper limit of normal excluded the presence of advanced LS, it was not associated with the primary endpoint (hazard ratio, 0.26; 95%CI, 0.01-1.33). However, LS was associated with the development of decompensated liver disease (hazard ratio, 1.55; 95%CI, 1.41-1.70). The optimal LS thresholds that stratified patients at a low, medium and high risk for hepatic decompensation were <4.5, 4.5-6.0 and >6.0 kPa (respectively).
CONCLUSION: Magnetic resonance elastography is able to detect cirrhosis with high specificity and an alkaline phosphatase <1.5 times the upper limit of normal makes the presence of advanced LS unlikely. Moreover, LS obtained by MRE is predictive of hepatic decompensation in PSC.
© 2015 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  liver stiffness; magnetic resonance elastography; primary sclerosing cholangitis

Mesh:

Year:  2016        PMID: 26691631      PMCID: PMC4885758          DOI: 10.1111/jgh.13263

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  25 in total

1.  Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis.

Authors:  Eva Recio; Juan Macías; Antonio Rivero-Juárez; Francisco Téllez; Dolores Merino; Mjosé Ríos; Manuel Márquez; Mohamed Omar; Antonio Rivero; Sandra Lorenzo; Nicolás Merchante; Juan A Pineda
Journal:  Liver Int       Date:  2012-03-09       Impact factor: 5.828

2.  Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.

Authors:  Christophe Corpechot; Ahmed El Naggar; Armelle Poujol-Robert; Marianne Ziol; Dominique Wendum; Olivier Chazouillères; Victor de Lédinghen; Daniel Dhumeaux; Patrick Marcellin; Michel Beaugrand; Raoul Poupon
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

3.  Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

Authors:  Laurent Huwart; Christine Sempoux; Eric Vicaut; Najat Salameh; Laurence Annet; Etienne Danse; Frank Peeters; Leon C ter Beek; Jacques Rahier; Ralph Sinkus; Yves Horsmans; Bernard E Van Beers
Journal:  Gastroenterology       Date:  2008-04-04       Impact factor: 22.682

4.  Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations.

Authors:  Hanno Ehlken; Ansgar W Lohse; Christoph Schramm
Journal:  Gastroenterology       Date:  2014-06-25       Impact factor: 22.682

5.  Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis.

Authors:  M Kaya; B T Petersen; P Angulo; T H Baron; J C Andrews; C J Gostout; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

Review 6.  Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  P J Scheuer
Journal:  Mayo Clin Proc       Date:  1998-02       Impact factor: 7.616

Review 7.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

8.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

9.  Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.

Authors:  Adolf Stiehl; Gerda Rudolph; Petra Klöters-Plachky; Peter Sauer; Siegfried Walker
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

10.  Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Said Al Mamari; Jelena Djordjevic; John S Halliday; Roger W Chapman
Journal:  J Hepatol       Date:  2012-10-22       Impact factor: 25.083

View more
  26 in total

1.  MR elastography in primary sclerosing cholangitis: correlating liver stiffness with bile duct strictures and parenchymal changes.

Authors:  Candice A Bookwalter; Sudhakar K Venkatesh; John E Eaton; Thomas D Smyrk; Richard L Ehman
Journal:  Abdom Radiol (NY)       Date:  2018-12

Review 2.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 3.  MR elastography of liver: current status and future perspectives.

Authors:  Ilkay S Idilman; Jiahui Li; Meng Yin; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2020-07-23

Review 4.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

Review 5.  Comparison of gradient-recalled echo and spin-echo echo-planar imaging MR elastography in staging liver fibrosis: a meta-analysis.

Authors:  Yong Seek Kim; Yu Na Jang; Ji Soo Song
Journal:  Eur Radiol       Date:  2017-11-21       Impact factor: 5.315

Review 6.  Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions.

Authors:  Paul Kennedy; Mathilde Wagner; Laurent Castéra; Cheng William Hong; Curtis L Johnson; Claude B Sirlin; Bachir Taouli
Journal:  Radiology       Date:  2018-03       Impact factor: 11.105

7.  The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis.

Authors:  Kartik S Jhaveri; Hooman Hosseini-Nik; Nima Sadoughi; Harry Janssen; Jordan J Feld; Sandra Fischer; Ravi Menezes; Angela C Cheung
Journal:  Eur Radiol       Date:  2018-07-26       Impact factor: 5.315

8.  Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis.

Authors:  John E Eaton; Aditi Sen; Safa Hoodeshenas; Cathy D Schleck; William S Harmsen; Gregory J Gores; Nicholas F LaRusso; Andrea A Gossard; Konstantinos N Lazaridis; Sudhakar K Venkatesh
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-01       Impact factor: 11.382

Review 9.  Magnetic Resonance Elastography of Liver: Current Update.

Authors:  Safa Hoodeshenas; Meng Yin; Sudhakar Kundapur Venkatesh
Journal:  Top Magn Reson Imaging       Date:  2018-10

Review 10.  Primary Sclerosing Cholangitis.

Authors:  Konstantinos N Lazaridis; Nicholas F LaRusso
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.